On October 10, 2025, Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a pioneering late-stage biotechnology company, announced a significant move to enhance its leadership team. The company’s Compensation Committee has approved inducement equity incentive awards for its newly appointed Chief Medical Officer, Dr. Syed Rizvi. This strategic decision underscores Rocket’s commitment to bolstering its operational capabilities as it advances its innovative pipeline of genetic therapies targeting rare disorders.

2. Details of the Inducement Grants

The inducement awards granted to Dr. Rizvi comprise three key components:

On-Hire Inducement Option: Dr. Rizvi will receive a nonstatutory stock option allowing him to purchase up to 383,854 shares of Rocket common stock. The exercise price for this option is determined by the closing share price on the Nasdaq Capital Market as of the grant date, October 6, 2025.

On-Hire Inducement RSUs: In addition to the stock options, Dr. Rizvi has been awarded 283,018 restricted stock units (RSUs).

Additional Inducement RSUs: Finally, he will receive 62,893 additional RSUs as part of the inducement package.

These awards are structured to incentivize Dr. Rizvi’s long-term commitment and performance with the company. The vesting schedule for both the On-Hire Inducement Options and RSUs is as follows:

On-Hire Inducement Option: 1/3rd of the shares will vest on the first anniversary of the grant date, with the remaining shares vesting quarterly over the subsequent two years, contingent on Dr. Rizvi's continuous service.

On-Hire Inducement RSUs: The vesting structure mirrors that of the options, with 1/3rd vesting on the first anniversary and the remainder over the next two years.

Additional Inducement RSUs: Here, 50% will vest on the first anniversary, with the remaining shares vesting one year later.

This incentivization aligns with Nasdaq Listing Rule 5635(c)(4), which necessitates such awards for newly hired executives as a material inducement for employment.

3. The Vision of Rocket Pharmaceuticals

Rocket Pharmaceuticals is dedicated to developing transformative genetic therapies to address rare diseases with high unmet needs. The company utilizes a multi-platform approach, focusing on both adeno-associated viral (AAV) and lentiviral (LV) vectors, to design optimal therapies for various conditions.

Current Pipeline and Focus Areas

Cardiovascular Portfolio

Rocket is advancing a late-stage clinical program targeting Danon Disease, a serious heart condition characterized by heart thickening. Additionally, the company is exploring an early-stage program for PKP2-arrhythmogenic cardiomyopathy (ACM), which poses life-threatening risks through ventricular arrhythmias.

Hematology Portfolio

In the hematology domain, Rocket is focusing on severe pediatric disorders, including:

Leukocyte Adhesion Deficiency-I (LAD-I): A genetic disorder that leads to recurrent infections.

Fanconi Anemia (FA): A genetic disease causing bone marrow failure and increased cancer risk.

Pyruvate Kinase Deficiency (PKD): A disorder resulting in anemia due to the destruction of red blood cells.

Future Outlook

Rocket's mission is clear: to transform the lives of patients suffering from devastating rare diseases. The company is also optimistic about its financial trajectory, anticipating that existing cash reserves will sustain operations through the second quarter of 2027.

4. Conclusion

The induction of Dr. Syed Rizvi into Rocket Pharmaceuticals’ executive team, accompanied by a robust equity incentive package, marks a pivotal moment for the company. As Rocket continues to build its pipeline of innovative therapies, the leadership of seasoned professionals like Dr. Rizvi will be crucial in navigating the complexities of biotechnology and rare disease treatment. Investors and stakeholders alike will be keenly watching Rocket’s progress as it endeavors to fulfill its ambitious goals in the genetic therapy landscape.

Original press release